Page 15 - சீன கலைக்கழகம் ஆஃப் மருத்துவ அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) May 19, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 – 8, 2021. “We are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this year’s ASCO, including multiple novel combinations of tislelizumab with our investigational Fc-competent anti-TIGIT-antibody ociperlimab and other therapeutic agents, and the ongoing evaluation of our next-generation BTK inhibitor zanubrutinib,” commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. “We believe that these presentations underscore the breadth and diversity, as well as the remarkable progress and momentum, in BeiGeneâ�

United statesLin shenSoult ukpyolsiSouth koreaSouth australiaUnited kingdomMarka socinskiKeun wook leeFortunato ciardielloJie wangLai wangLingying wuTao sunRuihua xuMazyar shadmanJian li